心玮医疗-B(6609.HK)今日早盘一度大涨14.1%至57.85港元。心玮医疗昨日晚间公告，集团预期于截至2025年12月31日止年度录得收益介乎约4亿元(人民 币，下同)至4.1亿元，较截至2024年12月31日止年度的收益2.78亿元增加至少43.9%。集团亦预计于报告期间录得除税前利润约8000万元，与截至2024年12月 31日止年度的除税前净亏损1200万元比较有大幅增长。 公司同日亦宣布，集团开发的自膨式颅内药物洗脱支架的注册申请已获中华人民共和国国家药品监督管理局受理。自膨式颅内药物洗脱支架用于颅内动脉粥 样硬化性狭窄的治疗，对狭窄和梗阻的管腔具有支撑和开通的作用，并且能有效预防支架内的管腔再狭窄。根据公开信息查询，目前全球范围内尚无类似产 品获批上市，公司对该类型产品的研发进度处于行业内领先水平。(格隆汇) ...

近日，心玮医疗发布公告称，公司预计截至2025年12月31日止年度将录得收益约4亿元至4.1亿元，较截 至2024年12月31日止年度的收益2.78亿元增加至少43.9%。 此外，预计除税前利润约8000万元，相较于截至2024年12月31日止年度的除税前净亏损1200万元有大幅 增长。 转亏为盈的主要原因包括缺血性卒中新产品与技术的推出、颅内支架的规模化商业化及其他出血性卒中 产品销量的增加，以及介入通路产品销售的持续增长。 ...

智通财经APP获悉，心玮医疗-B(06609)涨超12%，截至发稿，涨11.54%，报56.55港元，成交额286.47万 港元。 此外，心玮医疗还宣布，集团开发的自膨式颅内药物洗脱支架的注册申请已获国家药监局受理。自膨式 颅内药物洗脱支架用于颅内动脉粥样硬化性狭窄的治疗，对狭窄和梗阻的管腔具有支撑和开通的作用， 并且能有效预防支架内的管腔再狭窄。根据公开信息查询，目前全球范围内尚无类似产品获批上市，公 司对该类型产品的研发进度处于行业内领先水平。 消息面上，心玮医疗公布，集团预期于截至2025年12月31日止年度取得收益介乎约人民币4亿元至人民 币4.1亿元，同比增加至少43.9%；除税前利润约人民币8000万元，同比扭亏为盈。收益增长主要由于缺 血性卒中推出的新产品与技术及缺血性卒中产品的市场份额提升；颅内支架的规模化商业化及其他出血 性卒中产品销量的增加；及介入通路产品销售的持续增长；及集团通过销售成本及行政开支的有效成本 控制措施，降低了费用比率。 ...

此外，心玮医疗还宣布，集团开发的自膨式颅内药物洗脱支架的注册申请已获国家药监局受理。自膨式 颅内药物洗脱支架用于颅内动脉粥样硬化性狭窄的治疗，对狭窄和梗阻的管腔具有支撑和开通的作用， 并且能有效预防支架内的管腔再狭窄。根据公开信息查询，目前全球范围内尚无类似产品获批上市，公 司对该类型产品的研发进度处于行业内领先水平。 消息面上，心玮医疗公布，集团预期于截至2025年12月31日止年度取得收益介乎约人民币4亿元至人民 币4.1亿元，同比增加至少43.9%；除税前利润约人民币8000万元，同比扭亏为盈。收益增长主要由于缺 血性卒中推出的新产品与技术及缺血性卒中产品的市场份额提升；颅内支架的规模化商业化及其他出血 性卒中产品销量的增加；及介入通路产品销售的持续增长；及集团通过销售成本及行政开支的有效成本 控制措施，降低了费用比率。 心玮医疗-B(06609)涨超12%，截至发稿，涨11.54%，报56.55港元，成交额286.47万港元。 ...

Core Viewpoint - The company, 心玮医疗-B (06609), anticipates significant revenue growth for the fiscal year ending December 31, 2025, projecting earnings between approximately RMB 400 million and RMB 410 million, representing an increase of at least 43.9% compared to RMB 278 million for the fiscal year ending December 31, 2024 [1] Revenue Growth Drivers - The revenue growth is driven by the launch of new products and technologies for ischemic stroke and an increase in market share for ischemic stroke products [1] - The commercialization of intracranial stents and increased sales of other hemorrhagic stroke products contribute to the revenue growth [1] - Continuous growth in sales of interventional access products also supports the revenue increase [1] - Effective cost control measures in sales costs and administrative expenses have reduced the company's expense ratio [1] Profitability Expectations - The company expects to achieve a pre-tax profit of approximately RMB 80 million during the reporting period, a significant improvement compared to a pre-tax net loss of RMB 12 million for the fiscal year ending December 31, 2024 [1]

Core Viewpoint - The company expects significant revenue growth and a turnaround in profitability for the fiscal year ending December 31, 2025, driven by new product launches and market share gains in the ischemic stroke segment [1] Revenue Forecast - The company anticipates revenue between approximately RMB 400 million and RMB 410 million for the fiscal year ending December 31, 2025, representing an increase of at least 43.9% compared to the revenue of RMB 278 million for the fiscal year ending December 31, 2024 [1] Profitability Outlook - The company projects a pre-tax profit of approximately RMB 80 million for the reporting period, a significant improvement compared to a pre-tax net loss of RMB 12 million for the fiscal year ending December 31, 2024 [1] Growth Drivers - Revenue growth is driven by several factors, including the launch of new products and technologies for ischemic stroke, increased market share in ischemic stroke products, commercialization of intracranial stents, rising sales of other hemorrhagic stroke products, and sustained growth in interventional access product sales [1] - The company has also implemented effective cost control measures, reducing the expense ratio through lower sales costs and administrative expenses [1]

Core Viewpoint - The company expects significant revenue growth and a turnaround to profitability for the fiscal year ending December 31, 2025, driven by new product launches and effective cost control measures [1] Group 1: Revenue Expectations - The company anticipates revenue between approximately RMB 400 million and RMB 410 million for the fiscal year ending December 31, 2025, representing an increase of at least 43.9% compared to the revenue of RMB 278 million for the fiscal year ending December 31, 2024 [1] Group 2: Profitability Outlook - The company projects a pre-tax profit of approximately RMB 80 million for the fiscal year ending December 31, 2025, a significant improvement from a pre-tax net loss of RMB 12 million for the fiscal year ending December 31, 2024 [1] Group 3: Growth Drivers - Revenue growth is driven by several factors: 1. Launch of new products and technologies for ischemic stroke and an increase in market share for ischemic stroke products 2. Commercialization of intracranial stents and increased sales of other hemorrhagic stroke products 3. Continued growth in sales of interventional pathway products [1] - The company has effectively controlled costs through measures that reduced the expense ratio [1]

智通财经APP讯，心玮医疗-B(06609)发布公告，本集团开发的自膨式颅内药物洗脱支架的注册申请已获 中国国家药品监督管理局(国家药监局)受理。 自膨式颅内药物洗脱支架用于颅内动脉粥样硬化性狭窄的治疗，对狭窄和梗阻的管腔具有支撑和开通的 作用，并且能有效预防支架内的管腔再狭窄。根据公开信息查询，目前全球范围内尚无类似产品获批上 市，本公司对该类型产品的研发进度处于行业内领先水平。 ...

自膨式颅内药物洗脱支架用于颅内动脉粥样硬化性狭窄的治疗，对狭窄和梗阻的管腔具有支撑和开通的 作用，并且能有效预防支架内的管腔再狭窄。根据公开信息查询，目前全球范围内尚无类似产品获批上 市，本公司对该类型产品的研发进度处于行业内领先水平。 心玮医疗-B(06609)发布公告，本集团开发的自膨式颅内药物洗脱支架的注册申请已获中国国家药品监 督管理局(国家药监局)受理。 ...

格隆汇1月20日丨心玮医疗-B(06609.HK)宣布，集团开发的自膨式颅内药物洗脱支架的注册申请已获中 华人民共和国国家药品监督管理局受理。 自膨式颅内药物洗脱支架用于颅内动脉粥样硬化性狭窄的治疗，对狭窄和梗阻的管腔具有支撑和开通的 作用，并且能有效预防支架内的管腔再狭窄。根据公开信息查询，目前全球范围内尚无类似产品获批上 市，公司对该类型产品的研发进度处于行业内领先水平。 ...